Annotation Detail
Information
- Associated Genes
- IDH1
- Associated Variants
-
IDH1 R132
IDH1 R132 - Associated Disease
- high grade glioma
- Source Database
- CIViC Evidence
- Description
- In a clinical study of 63 recurrent glioma patients, the combined cohort of patients treated with either bevacizumab or sunitinib showed that those harboring IDH1 codon 132 mutation were associated with improved overall survival (OS 7.53 vs. 4.83 months; P=0.04), as compared to patients with wild-type IDH1.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/2020
- Gene URL
- https://civic.genome.wustl.edu/links/genes/26
- Variant URL
- https://civic.genome.wustl.edu/links/variants/58
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Malignant Glioma
- Evidence Direction
- Supports
- Drug
- Bevacizumab,Sunitinib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 22199315
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Bevacizumab | Sensitivity | true |
| Sunitinib | Sensitivity | true |